O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+55.65%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$6.98B
AUM Growth
+$6.98B
(+34%)
Cap. Flow
+$27.1M
Cap. Flow
% of AUM
0.39%
Top 10 Holdings %
Top 10 Hldgs %
37.73%
Holding
152
New
37
Increased
17
Reduced
34
Closed
13
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$109M |
| 2 |
89bio
ETNB
|
$105M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$104M |
| 4 |
Danaher
DHR
|
$98.1M |
| 5 |
Glaukos
GKOS
|
$84.3M |
Top Sells
| 1 |
AVDR
Avedro, Inc Common Stock
AVDR
|
$96.3M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
$79.2M |
| 3 |
Neurocrine Biosciences
NBIX
|
$68.7M |
| 4 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$58.9M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$56.6M |
Sector Composition
| 1 | Healthcare | 98.02% |
| 2 | Financials | 1.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
argenx
ARGX
$44.2B
| $41.1M | 0.59% |
256,300
-54,100
| -17% | -$8.68M |
|
52
TELA Bio
TELA
$65.4M
| $39.2M | 0.56% |
+3,027,542
| New | +$39.2M |
|
53
Corvus Pharmaceuticals
CRVS
$419M
| $36.8M | 0.53% |
6,767,584
| – | – |
|
|
HARP
54
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $36.2M | 0.52% |
244,641
| – | – |
|
55
Elevance Health
ELV
$72.4B
| $32.2M | 0.46% |
106,600
-148,000
| -58% | -$44.7M |
|
56
Amgen
AMGN
$153B
| $29.4M | 0.42% |
122,100
| – | – |
|
57
HCA Healthcare
HCA
$95.4B
| $28.1M | 0.4% |
+190,000
| New | +$28.1M |
|
58
IQVIA
IQV
$31.4B
| $27M | 0.39% |
175,000
| – | – |
|
59
Applied Therapeutics
APLT
$73.7M
| $26.9M | 0.38% |
+987,186
| New | +$26.9M |
|
60
Zimmer Biomet
ZBH
$20.8B
| $26.7M | 0.38% |
+184,061
| New | +$26.7M |
|
61
Verrica Pharmaceuticals
VRCA
$49.4M
| $23.5M | 0.34% |
147,973
| – | – |
|
62
BiomX
PHGE
$14.1M
| $22.4M | 0.32% |
+231,349
| New | +$22.4M |
|
63
Spyre Therapeutics
SYRE
$1.02B
| $21.9M | 0.31% |
114,621
| – | – |
|
64
Zai Lab
ZLAB
$3.48B
| $21.4M | 0.31% |
514,000
| – | – |
|
65
Gilead Sciences
GILD
$140B
| $21.2M | 0.3% |
326,100
| – | – |
|
66
Alcon
ALC
$38.9B
| $19.9M | 0.28% |
351,380
| – | – |
|
67
scPharmaceuticals
SCPH
$296M
| $19.3M | 0.28% |
3,409,865
| – | – |
|
68
Biogen
BIIB
$20.8B
| $19.1M | 0.27% |
64,500
+28,300
| +78% | +$8.4M |
|
69
Novo Nordisk
NVO
$252B
| $19.1M | 0.27% |
660,000
| – | – |
|
70
Avantor
AVTR
$8.74B
| $18.4M | 0.26% |
+1,012,800
| New | +$18.4M |
|
|
SVA
71
DELISTED
Sinovac Biotech, Ltd
SVA
| $17.2M | 0.24% |
2,839,500
| – | – |
|
72
Xtant Medical Holdings
XTNT
$82.4M
| $14.7M | 0.21% |
9,207,012
| – | – |
|
|
ALPN
73
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $14.1M | 0.2% |
3,670,955
| – | – |
|
|
TECX
74
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $12.8M | 0.18% |
52,892
+5,334
| +11% | +$1.29M |
|
75
KALA BIO
KALA
$105M
| $12.7M | 0.18% |
69,026
| – | – |
|